MRC Agrotech's revenue doubled. The auditor says half of it arrived in March.
A revenue surge masks a stark concentration risk. The auditor's report says 44.6% of taxable sales were booked in the final month of the year.
— 2 earlier stories on MRC Agrotech Ltd. →What's new
- Standalone revenue more than doubled to ₹85.46 crore in FY26 from ₹32.45 crore a year earlier.
- The auditor flagged that 44.6% of taxable supplies were booked in the final month.
- Two related counterparties accounted for 53% of total purchases.
Why this matters
The auditor's emphasis-of-matter paragraphs reframe the top-line surge. When nearly half of a year's sales land in March and just two suppliers represent over half of purchases, the growth looks less like a business win and more like a timing event.
What we're watching
- Whether the March sales concentration repeats in FY27.
- If the two dominant suppliers remain in the mix.
- How the share-swap acquisition of Marsapi Lifesciences performs.
The full read
MRC Agrotech's revenue more than doubled to ₹85.46 crore in FY26. Profit grew too, to ₹1.17 crore from ₹0.88 crore, but the gain is modest against that scale-up. The real story is in the auditor's report. 44.6% of the year's taxable supplies were booked in March. And 53% of purchases went to just two suppliers, who are related to each other. The filing also incorporates the share-swap acquisition of Marsapi Lifesciences, a deal done without cash. For a company with a ₹32.45 crore revenue base just a year ago, the growth is real. The auditor's warnings about concentration in both sales and purchases suggest the foundation is not. Hardly. The growth looks like a single-month event.
Questions answered
- Why did the auditor flag MRC Agrotech's revenue?
- The auditor's report emphasized that 44.6% of the company's taxable supplies for the entire year were booked in March. This concentration raises questions about the consistency and timing of the company's sales.
- What is the significance of the two counterparties?
- Two entities, related to each other but not to MRC Agrotech, were responsible for 53% of the company's total purchases. This heavy reliance on a small number of suppliers is an operational risk highlighted in the audit.
- How did MRC Agrotech acquire Marsapi Lifesciences?
- MRC Agrotech acquired Marsapi Lifesciences as a wholly owned subsidiary through a share-swap deal, meaning no cash consideration was paid. The transaction is incorporated into the audited results.
- How strong was the profit growth compared to revenue?
- Net profit rose from ₹0.88 crore to ₹1.17 crore. While positive, profit grew far slower than the more-than-doubled revenue increase, suggesting margins came under pressure.
Story so far
All notes on MRCAGRO →- 6 Jun 2026 · 11:37 AM IST MRC Agrotech's revenue doubled. The auditor says half of it arrived in March.
- 3d ago MRC Agrotech's 163% revenue jump hides a big March problem.
- 6d ago MRC Agrotech misses FY26 audit deadline